FDA Releases New Guidance on Drug Development Tools - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Releases New Guidance on Drug Development Tools


FDA has released guidance on the process for qualifying drug development tools (DDTs) intended for potential use, over time, in multiple drug development programs. Guidance for Industry and FDA Staff, Qualification Process for Drug Development Tools defines DDTs as methods, materials, or measures that aid drug development that include, but are not limited to, biomarkers, clinical outcome assessments (COAs), and animal models for drug development under the Animal Rule.

FDA provides a framework for interactions between the Center for Drug Evaluation and Research (CDER) and the submitter of the DDT for qualification. The guidance outlines the kinds of data that should be submitted to support qualification of a DDT. It also creates a process for CDER’s formal review of the data.

The guidance states, “Qualification does not pertain to the process for review of DDTs that are submitted as part of regulatory applications for a specific drug development program. Furthermore, this guidance does not address the evidentiary standards or performance requirements needed for purposes of qualification.”

FDA also released an attachment to the guidance on the qualification of exacerbations of chronic pulmonary disease tool.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here